The grant to GTx comprises separate payments of $244,000 for each of five cancer and cancer supportive care research and development programs.
Gtx CEO Mitchell Steiner said that they are pleased to receive this recognition and these funds will help GTx advance their pipeline of clinical and preclinical product candidates.
Gtx is a biopharmaceutical company engaged in discovery, development and commercialisation of small molecules that selectively target hormone pathways for the treatment and prevention of cancer.